Allosteric SHP2 inhibitor, IACS-13909, overcomes EGFR-dependent and EGFR-independent resistance mechanisms toward osimertinib

Yuting Sun, Brooke A. Meyers, Barbara Czako, Paul Leonard, Faika Mseeh, Angela L. Harris, Qi Wu, Sarah Johnson, Connor A. Parker, Jason B. Cross, Maria Emilia Di Francesco, Benjamin J. Bivona, Christopher A. Bristow, Jason P. Burke, Caroline C. Carrillo, Christopher L. Carroll, Qing Chang, Ningping Feng, Guang Gao, Sonal GeraVirginia Giuliani, Justin K. Huang, Yongying Jiang, Zhijun Kang, Jeffrey J. Kovacs, Chiu Yi Liu, Anastasia M. Lopez, Xiaoyan Ma, Pijus K. Mandal, Timothy McAfoos, Meredith A. Miller, Robert A. Mullinax, Michael Peoples, Vandhana Ramamoorthy, Sahil Seth, Nakia D. Spencer, Erika Suzuki, Christopher C. Williams, Simon S. Yu, Andy M. Zuniga, Giulio F. Draetta, Joseph R. Marszalek, Timothy P. Heffernan, Nancy E. Kohl, Philip Jones

Research output: Contribution to journal › Article › peer-review

47 Scopus citations

Fingerprint

Dive into the research topics of 'Allosteric SHP2 inhibitor, IACS-13909, overcomes EGFR-dependent and EGFR-independent resistance mechanisms toward osimertinib'. Together they form a unique fingerprint.

Medicine & Life Sciences